biotech / news / / Devdiscourse
Moderna's mRNA-based seasonal flu vaccine demonstrated superior efficacy compared to conventional flu shots.
Moderna's mRNA flu vaccine showed 26.6% higher effectiveness than GSK's standard-dose flu shot.
KEY POINTS
- Over 40,000 adults aged 50 and older participated in the late-stage global trial.
- FDA initially rejected Moderna's vaccine due to concerns over how the vaccine's performance was compared.
- If approved, Moderna's would be the first U.S. seasonal flu vaccine using mRNA technology.
- Ongoing regulatory reviews in the EU, Canada, and Australia could influence upcoming approvals.
COMPANIES
Summarized by Newsio from Devdiscourse. How we summarize →